JPS5859921A - アマチヤヅルサポニンを含有する抗癌剤 - Google Patents
アマチヤヅルサポニンを含有する抗癌剤Info
- Publication number
- JPS5859921A JPS5859921A JP56157925A JP15792581A JPS5859921A JP S5859921 A JPS5859921 A JP S5859921A JP 56157925 A JP56157925 A JP 56157925A JP 15792581 A JP15792581 A JP 15792581A JP S5859921 A JPS5859921 A JP S5859921A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gypenoside
- active
- cells
- ch2oh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006509 Gynostemma pentaphyllum Species 0.000 title abstract description 20
- 229930182490 saponin Natural products 0.000 title abstract description 7
- 150000007949 saponins Chemical class 0.000 title abstract description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract description 6
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 title abstract description 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 230000003327 cancerostatic effect Effects 0.000 title abstract 2
- 229930187479 gypenoside Natural products 0.000 claims abstract description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 24
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 9
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract description 7
- 206010046766 uterine cancer Diseases 0.000 abstract description 7
- 201000007270 liver cancer Diseases 0.000 abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 abstract description 6
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical group C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 201000001441 melanoma Diseases 0.000 abstract description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 3
- 206010073069 Hepatic cancer Diseases 0.000 abstract 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 23
- 239000000284 extract Substances 0.000 description 17
- 150000001721 carbon Chemical group 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- RTBXOFMHEMBXKG-UHFFFAOYSA-N 2-methyl-1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CC(C1=CC=C3)C)=C1C3=C2 RTBXOFMHEMBXKG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010454 Experimental Liver Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- PFWQCAQPDUBXKO-UHFFFAOYSA-N Gypenoside XX Natural products CC1OC(OCC2OC(OC3CCC4(C)C(CCC5(C)C4CC(O)C6C(CCC56C)C(C)(CCC=C(/C)CO)OC7OC(COC8OC(CO)C(O)C(O)C8O)C(O)C(O)C7O)C3(C)C)C(OC9OC(CO)C(O)C(O)C9O)C(O)C2O)C(O)C(O)C1O PFWQCAQPDUBXKO-UHFFFAOYSA-N 0.000 description 1
- KHPWSKNLAFECBO-NSMVKXLTSA-N Gypenoside XXV Chemical compound C([C@](O)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C)[C@@H]([C@]4(CC[C@@H](C(C)(C)[C@@H]4CC3)O[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=O)CC2)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KHPWSKNLAFECBO-NSMVKXLTSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56157925A JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56157925A JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5859921A true JPS5859921A (ja) | 1983-04-09 |
| JPS6312445B2 JPS6312445B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-03-18 |
Family
ID=15660457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56157925A Granted JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5859921A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04501858A (ja) * | 1989-07-21 | 1992-04-02 | マリゲン ソシエテ アノニム | ステロールの脂肪酸エステルの抗腫瘍剤のための自発的分散性濃縮物及びそれを含む医薬組成物 |
| US6177418B1 (en) * | 1995-09-15 | 2001-01-23 | Leo Pharmaceutical Products Ltd. A/S | Tetracyclic triterpenes as cholesterol-lowering and anti-atherosclerosis agents |
| KR101128920B1 (ko) | 2009-12-15 | 2012-04-23 | 충남대학교산학협력단 | 지페노사이드, 이의 제조방법 및 용도 |
| CN102579471A (zh) * | 2012-01-16 | 2012-07-18 | 中央民族大学 | 四种绞股蓝皂苷类化合物制备治疗肿瘤药物的用途 |
| CN103012537A (zh) * | 2012-12-20 | 2013-04-03 | 上海交通大学 | 达玛烷型三萜类化合物及其制备方法和应用 |
| CN105153271A (zh) * | 2015-09-17 | 2015-12-16 | 沈阳农业大学 | 两个新的达玛烷型三萜类化合物及其制备方法和用途 |
| EP3501296A1 (en) * | 2017-12-22 | 2019-06-26 | Analyticon Discovery GmbH | Novel triterpene-glycosides as sweeteners or sweetener enhancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857399A (ja) * | 1981-10-01 | 1983-04-05 | Osaka Chem Lab | ニンジンサポニン、その分離法及び製造法並びに用途 |
-
1981
- 1981-10-02 JP JP56157925A patent/JPS5859921A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857399A (ja) * | 1981-10-01 | 1983-04-05 | Osaka Chem Lab | ニンジンサポニン、その分離法及び製造法並びに用途 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04501858A (ja) * | 1989-07-21 | 1992-04-02 | マリゲン ソシエテ アノニム | ステロールの脂肪酸エステルの抗腫瘍剤のための自発的分散性濃縮物及びそれを含む医薬組成物 |
| US6177418B1 (en) * | 1995-09-15 | 2001-01-23 | Leo Pharmaceutical Products Ltd. A/S | Tetracyclic triterpenes as cholesterol-lowering and anti-atherosclerosis agents |
| KR101128920B1 (ko) | 2009-12-15 | 2012-04-23 | 충남대학교산학협력단 | 지페노사이드, 이의 제조방법 및 용도 |
| CN102579471A (zh) * | 2012-01-16 | 2012-07-18 | 中央民族大学 | 四种绞股蓝皂苷类化合物制备治疗肿瘤药物的用途 |
| CN103012537A (zh) * | 2012-12-20 | 2013-04-03 | 上海交通大学 | 达玛烷型三萜类化合物及其制备方法和应用 |
| CN105153271A (zh) * | 2015-09-17 | 2015-12-16 | 沈阳农业大学 | 两个新的达玛烷型三萜类化合物及其制备方法和用途 |
| EP3501296A1 (en) * | 2017-12-22 | 2019-06-26 | Analyticon Discovery GmbH | Novel triterpene-glycosides as sweeteners or sweetener enhancer |
| WO2019120716A1 (en) * | 2017-12-22 | 2019-06-27 | Analyticon Discovery Gmbh | Novel triterpene-glycosides as sweeteners or sweetener enhancer |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6312445B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101035548B (zh) | 甾体皂苷药物组合物及其制备方法和应用 | |
| JP2024505106A (ja) | アズレン系化合物及びその作製方法と使用 | |
| IE48526B1 (en) | Natural polar fraction having ant-psoriatic activity | |
| CA2502703C (en) | A natural compound for prevention and treatment of diabetes, process for preparing the same, and pharmaceutical use thereof | |
| JPS5859921A (ja) | アマチヤヅルサポニンを含有する抗癌剤 | |
| CN113387997B (zh) | 一种具有改善糖脂代谢紊乱作用的三萜皂苷化合物及其制备和应用 | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN111454317B (zh) | 具有抗炎活性的人参二醇型三萜皂苷、三七叶提取物、药物组合物和化妆品组合物 | |
| CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
| WO1998024795A1 (en) | Novel triterpene glycoside compound, process for preparation thereof and anti-cancer composition containing the same | |
| CN102295677B (zh) | 北美盐角草中一种降三萜皂苷及其制备方法和用途 | |
| CN106543117B (zh) | 具有抗肿瘤活性的间双四氢呋喃型番荔枝内酯类化合物及其制备方法与应用 | |
| CN101390871B (zh) | 含有杂质人参皂苷Rd的人参皂苷Rb1 | |
| CN1318034C (zh) | 用桑白皮提取物制备的药物制剂 | |
| CN120157729B (zh) | 灵芝三萜类化合物及其制备方法与防治肝损伤的用途 | |
| CN106977561B (zh) | Sutherlandin-5-p-hydroxybenzoate的制备及其在制备治疗类风湿关节炎药物中的应用 | |
| CN114436887B (zh) | 一种中药薏苡仁中的新生物碱及其提取纯化方法和应用 | |
| CN101392013A (zh) | 含有杂质人参皂苷Rh1的人参皂苷Rb1 | |
| JPS61106516A (ja) | 血糖降下剤 | |
| CN113861261B (zh) | 山绿茶三萜皂苷元类提取物、提取工艺、制剂及应用 | |
| CN107648291A (zh) | 常春藤皂苷元及其糖苷在制备抗炎抗氧化的药物中的应用 | |
| JPS62132829A (ja) | 肝炎の治療剤 | |
| JPS632928A (ja) | 鎮痛剤 | |
| JPS6312448B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS5872523A (ja) | 抗腫瘍剤 |